Remove Big Data Remove Dermatology Remove Generic Pharmaceutical Remove Trials
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. Toujeo generated Sanofi €1.12 Additional revenue came from the acquisition of Alexion Pharmaceuticals in July 2021. billion ($1.17 billion USD) in revenue in 2022.

Sales 98